Melissa L. Geddie - Concepedia

Concepedia

Author

Melissa L. Geddie

Merrimack Pharmaceuticals (United States)

Also Known As

M. Geddie, M.L. Geddie, Melissa Geddie, Melissa L Geddie, Melissa L. Geddie

27

Publications

1.4K

Citations

12

H-Index

48

Concepts

All Affiliations

Merrimack Pharmaceuticals (United States)Emory University Howard Hughes Medical Institute Whitehead Institute for Biomedical Research Massachusetts Institute of Technology

ML

About

Melissa L. Geddie is an author at Merrimack Pharmaceuticals (United States) specializing in medicine, molecular biology, and protein engineering.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	1.2K
2	Engineering	5	5	211
3	Natural Sciences	4	4	629
4	Social Sciences	1	1	156
5	Biochemistry	1	1	533

Melissa L. Geddie

×

13

Publications

1.4K

Citations

12

H-Index

	Year	Citations
α-Synuclein is part of a diverse and highly conserved interaction network that includes PARK9 and manganese toxicity Aaron D. Gitler, Alessandra Chesi, Melissa L. Geddie, Nature Genetics Neurodegenerative DiseasesMolecular NeuroscienceBiochemistryNatural SciencesMetalloprotein	2009	533
Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity Esti Yeger‐Lotem, Laura Riva, Linhui Julie Su, Nature Genetics Knockout MouseNeurodegenerative DiseasesFunctional GenomicsDisease MechanismMolecular Biology	2009	292
Polyamine pathway contributes to the pathogenesis of Parkinson disease Nicole Lewandowski, Shulin Ju, Miguel Verbitsky, Proceedings of the National Academy of Sciences NeurogenomicsMolecular BiologyNeurochemical BiomarkersSynaptic SignalingSocial Sciences	2010	156
A novel screening method to assess developability of antibody-like molecules Neeraj Kohli, Melissa L. Geddie, Maja Razlog, mAbs Immunocytochemical TechniqueEngineeringImmunologyImmunotherapyBioanalysis	2015	76
Rapid Evolution of β-Glucuronidase Specificity by Saturation Mutagenesis of an Active Site Loop Melissa L. Geddie, Ichiro Matsumura Journal of Biological Chemistry	2004	69
A Comparison of Directed Evolution Approaches Using the β-Glucuronidase Model System Lori A. Rowe, Melissa L. Geddie, Omar B. Alexander, Journal of Molecular Biology Differential EvolutionEvolution StrategyDirected Evolution ApproachesEngineeringNatural Sciences	2003	63
Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models Walid S. Kamoun, Dmitri B. Kirpotin, Zhaohua Huang, Nature Biomedical Engineering NanomedicineDrug TargetingNanotherapeuticsPolymer-drug ConjugateMedicine	2019	57
MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM Jessica B. Casaletto, Melissa L. Geddie, Adnan O. Abu‐Yousif, Proceedings of the National Academy of Sciences	2019	30
Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle Kathy Zhang, Melissa L. Geddie, Neeraj Kohli, mAbs NanoparticlesEngineeringImmunologyMolecular BiologyBiomedical Engineering	2014	28
Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting Melissa L. Geddie, Neeraj Kohli, Dmitri B. Kirpotin, mAbs NanoparticlesAntibody FragmentEngineeringImmunologyBiomedical Engineering	2016	27

Page 1